Cite
HARVARD Citation
Schuster, S. et al. (2021). Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet oncology. 22 (10), pp. 1403-1415. [Online].